Stamford, CT -- (SBWIRE) -- 01/14/2014 -- Jet Life Penny Stocks is engaged in providing the most up to date and useful information on the Best Penny Stocks that are poised to breakout. Our penny stock newsletter alerts the market with picks that Wall Street stock traders have ignored or haven’t found out about yet. Here are some of the most awesome penny stocks we came up with that the ‘underground penny stock experts’ are always bragging about in their penny stock newsletters. Have a look on today’s market movers: NovaGold Resources Inc. (USA) (NYSEMKT:NG), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Amyris Inc (NASDAQ:AMRS)
NovaGold Resources Inc. (USA) (NYSEMKT:NG) opened the session at $2.84, trading in a range of $2.80 - $2.97. The stock showed a positive performance of +4.66% in the last trading session from its previous close of $2.79 and closed at $2.92. The stock traded on a volume of 2.66 million shares and the average volume of the stock remained 1.67 million shares. NovaGold Resources Inc. (NovaGold) is engaged in the exploration and development of mineral properties. The Company has a portfolio of mineral properties located in Alaska, the United States and British Columbia, Canada. The Donlin Gold project in Alaska is held by a limited liability company owned equally by wholly owned subsidiaries of NovaGold and Barrick Gold Corporation (Barrick).
For How Long NG will Fight for Profitability? Read This Trend Analysis report
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) traded 2.07 million shares in the last business day while the average volume of the stock remained 1.10 million shares. The stock showed a positive movement of +4.27% to end at $10.51. The 52 week range of the stock remained $1.12 - $10.87. BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. BioCryst designs, optimizes and develops drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on therapeutic areas. Peramivir is its product, which is a neuraminidase inhibitor for the treatment of patients with influenza.
For How Long BCRX’s Gloss will Attract Investors? Find out via this report
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported 11.88 million shares were exchanged during the last trade, while the average volume is about 4.14 million shares. The stock escalated +3.92% and finished the day at $6.62. The beta of the stock is recorded at -0.40. Arena Pharmaceuticals, Inc. (Arena) is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors. Its wholly owned subsidiary, Arena Pharmaceuticals GmbH (Arena GmbH), has granted Eisai Inc., rights to commercialize BELVIQ in the United States. The Company’s oral drug candidates include APD811, an agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension, which is in Phase I; temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I trials.
For How Long ARNA’s Gloss will Attract Investors? Find out via this report
Amyris Inc (NASDAQ:AMRS) shares rose, +3.40 percent from its previous close of $7.41 to close at $4.56. Traded with volume of 1.09 million shares in the prior session and the average volume of the stock remained 592,249 shares. Amyris, Inc., formerly Amyris Biotechnologies, Inc. develops and provides renewable compounds for a variety of markets. As of December 31, 2012, the Company built and applied its industrial synthetic biology platform to provide alternatives to petroleum-sourced products used in specialty chemical and transportation fuel markets worldwide. The Company is focused on developing a range of products to address six markets: cosmetics, lubricants, flavors and fragrances, polymers, consumer products and transportation fuels.
Why Should Investors Buy AMRS After The Recent Gain? Just Go Here and Find Out
Jet Life Penny Stocks is always searching the market every day for massive penny stock runs before they happen so you don't have to. Our Penny Stock Newsletter also offers free Highly-Professional Grade stock charts and video charts from one of the most experienced and well-respected chartists in the penny stock industry.
Jet Life Penny Stocks is not a registered securities advisor. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides information on highlighted stocks via press releases, newsletters and company website, but this should not be construed as a recommendation to buy or sell. Please visit the company website for a more complete list of risks and disclosures.
Read full disclaimer at: http://www.jetlifepennystocks.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)